Annals of Hematology

, Volume 85, Issue 6, pp 357–365

Standard induction chemotherapy followed by attenuated consolidation in elderly patients with acute myeloid leukemia

Authors

    • Department of Internal MedicineAsan Medical Center
  • Seong-Jun Choi
    • Department of Internal MedicineAsan Medical Center
  • Jung-Hee Lee
    • Department of Internal MedicineAsan Medical Center
  • Jae-Hoo Park
    • Division of Hematology–Oncology, Ulsan University HospitalUniversity of Ulsan College of Medicine
  • Hawk Kim
    • Division of Hematology–Oncology, Ulsan University HospitalUniversity of Ulsan College of Medicine
  • Young-Don Joo
    • Department of Internal Medicine, Busan Paik HospitalInje University College of Medicine
  • Won Sik Lee
    • Department of Internal Medicine, Busan Paik HospitalInje University College of Medicine
  • Dae Young Zang
    • Department of Internal Medicine, Hallym University Medical CenterHallym University College of Medicine
  • Hyo Jung Kim
    • Department of Internal Medicine, Hallym University Medical CenterHallym University College of Medicine
  • Kyoo-Hyung Lee
    • Department of Internal MedicineAsan Medical Center
  • Cooperative Study Group A for Hematology
Original Article

DOI: 10.1007/s00277-006-0110-8

Cite this article as:
Lee, J., Choi, S., Lee, J. et al. Ann Hematol (2006) 85: 357. doi:10.1007/s00277-006-0110-8

Abstract

The benefits of intensive post-remission chemotherapy have not been verified in elderly patients with acute myeloid leukemia (AML). To reduce fatal complications caused by intensive post-remission therapy, we performed a prospective phase II multicenter trial of standard induction chemotherapy (‘7+3’ of cytarabine plus daunorubicin), followed by two cycles of attenuated consolidation therapy (‘5+1’ of cytarabine plus daunorubicin) for elderly patients with AML, excluding those with M3. Of the 41 patients enrolled in the study, 24 (58.5%) attained CR. Of these 24, 17 (70.8%) completed both planned cycles of consolidation therapy. After a median follow-up of 566 days (range, 63–1190 days) among surviving patients, 15 relapsed, with an actuarial 3-year disease-free survival rate of 22.5%. There were no fatal complications during consolidation therapy. Actuarial 3-year overall survival was 17.0%. These findings suggest that, when compared with previous findings using more intensive consolidation therapy, attenuated consolidation therapy does not compromise outcomes in elderly AML patients.

Keywords

Elderly patientsAcute myeloid leukemiaAttenuated consolidation therapy

Copyright information

© Springer-Verlag 2006